Abandoning personalization to get to precision in the pharmacotherapy of depression

World Psychiatry

Volumn 15, Issue 3, 2016, Pages 228-235

  Perlis, Roy H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antidepressants; biomarkers; major depression; personalized medicine; precision medicine; risk stratification; treatment matching

Indexed keywords

ANTIDEPRESSANT AGENT; C REACTIVE PROTEIN; CYTOCHROME P450; DESVENLAFAXINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ARTICLE; ATYPICAL DEPRESSION; CLINICAL DECISION MAKING; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL PROTOCOL; COHORT ANALYSIS; DEPRESSION; DEXAMETHASONE SUPPRESSION TEST; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; ELECTRONIC MEDICAL RECORD; EVIDENCE BASED MEDICINE; GENETIC VARIABILITY; HUMAN; MAJOR DEPRESSION; MELANCHOLIA; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NATURALISTIC INQUIRY; OUTCOME ASSESSMENT; PATIENT EDUCATION; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHARMACOGENOMICS; PHENOMENOLOGY; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SAMPLE SIZE; TREATMENT RESPONSE;

EID: 84988447135     PISSN: 17238617     EISSN: 20515545     Source Type: Journal    
DOI: 10.1002/wps.20345     Document Type: Article

References (52)

1. Johnson CF, Dougall NJ, Williams B et al. Patient factors associated with SSRI dose for depression treatment in general practice: a primary care cross sectional study. BMC Family Pract 2014;15:210.
2. von Wolff A, Meister R, Harter M et al. Treatment patterns in inpatient depression care. Int J Methods Psychiatr Res 2016;25:55-67.
3. Goldberg JF, Freeman MP, Balon R et al. The American Society of Clinical Psychopharmacology Survey of Psychopharmacologists' Practice Patterns for the Treatment of Mood Disorders. Depress Anxiety 2015;32:605-13.
4. Herbild L, Bech M, Gyrd-Hansen D. Estimating the Danish populations' preferences for pharmacogenetic testing using a discrete choice experiment. The case of treating depression. Value Health 2009;12:560-7.
5. National Research Council of the National Academies. Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease. Washington: National Academies Press, 2011.
6. US Food and Drug Administration. Table of pharmacogenomic biomarkers in drug labeling 2014. www.fda.gov.
7. Hicks JK, Swen JJ, Thorn CF et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther 2013;93:402-8.
8. Preskorn SH. Outpatient management of depression: a guide for the primary-care practitioner, 2nd ed. Caddo: Professional Communications, 1999.
9. Fountoulakis KN, Möller HJ. Antidepressant drugs and the response in the placebo group: the real problem lies in our understanding of the issue. J Psychopharmacol 2012;26:744-50.
10. Pande AC, Crockatt JG, Janney CA et al. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord 2000;2:249-55.
11. Ioannidis JP. Why most published research findings are false. PLoS Med 2005;2:e124.
12. Lee CS, Cheng AT. Variant GADL1 and response to lithium in bipolar I disorder. N Engl J Med 2014;370:1859-60.
13. Chen CH, Lee CS, Lee MT et al. Variant GADL1 and response to lithium therapy in bipolar I disorder. N Engl J Med 2014;370:119-28.
14. Fava M, Uebelacker LA, Alpert JE et al. Major depressive subtypes and treatment response. Biol Psychiatry 1997;42:568-76.
15. Perlis RH, Uher R, Ostacher M et al. Association between bipolar spectrum features and treatment outcomes in outpatients with major depressive disorder. Arch Gen Psychiatry 2011;68:351-60.
16. Fava M, Rush AJ, Alpert JE et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry 2008;165:342-51.
17. Uher R, Perlis RH, Henigsberg N et al. Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms. Psychol Med 2012;42:967-80.
18. Kraemer HC, Stice E, Kazdin A et al. How do risk factors work together? Mediators, moderators, and independent, overlapping, and proxy risk factors. Am J Psychiatry 2001;158:848-56.
19. Stiles-Shields C, Corden ME, Kwasny MJ et al. Predictors of outcome for telephone and face-to-face administered cognitive behavioral therapy for depression. Psychol Med 2015;45:3205-15.
20. Perlis RH. A clinical risk stratification tool for predicting treatment resistance in major depressive disorder. Biol Psychiatry 2013;74:7-14.
21. Pencina MJ, D'Agostino RB Sr, Demler OV. Novel metrics for evaluating improvement in discrimination: net reclassification and integrated discrimination improvement for normal variables and nested models. Stat Med 2012;31:101-13.
22. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007;115:928-35.
23. De Gregori M, Allegri M, De Gregori S et al. How and why to screen for CYP2D6 interindividual variability in patients under pharmacological treatments. Curr Drug Metab 2010;11:276-82.
24. Fava M, Alpert J, Nierenberg A et al. Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J Clin Psychopharmacol 2002;22:379-87.
25. Fava M, Rosenbaum JF, McGrath PJ et al. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry 1994;151:1372-4.
26. Berney P. Dose-response relationship of recent antidepressants in the short-term treatment of depression. Dialogues Clin Neurosci 2005;7:249-62.
27. Mrazek DA, Biernacka JM, O'Kane DJ et al. CYP2C19 variation and citalopram response. Pharmacogenet Genomics 2011;21:1-9.
28. Preskorn SH, Kane CP, Lobello K et al. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine. J Clin Psychiatry 2013;74:614-21.
29. Lobello KW, Preskorn SH, Guico-Pabia CJ et al. Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder. J Clin Psychiatry 2010;71:1482-7.
30. Baldessarini RJ, Arana GW. Does the dexamethasone suppression test have clinical utility in psychiatry? J Clin Psychiatry 1985;46:25-9.
31. Perlis RH. Translating biomarkers to clinical practice. Mol Psychiatry 2011;16:1076-87.
32. Uher R, Tansey KE, Malki K et al. Biomarkers predicting treatment outcome in depression: what is clinically significant? Pharmacogenomics 2012;13:233-40.
33. Cook IA, Hunter AM, Gilmer WS et al. Quantitative electroencephalogram biomarkers for predicting likelihood and speed of achieving sustained remission in major depression: a report from the biomarkers for rapid identification of treatment effectiveness in major depression (BRITE-MD) trial. J Clin Psychiatry 2013;74:51-6.
34. Hunter AM, Cook IA, Greenwald SD et al. The antidepressant treatment response index and treatment outcomes in a placebo-controlled trial of fluoxetine. J Clin Neurophysiol 2011;28:478-82.
35. Roberts JS, Chen CA, Uhlmann WR et al. Effectiveness of a condensed protocol for disclosing APOE genotype and providing risk education for Alzheimer disease. Genet Med 2012;14:742-8.
36. Rose D, Russo J, Wykes T. Taking part in a pharmacogenetic clinical trial: assessment of trial participants understanding of information disclosed during the informed consent process. BMC Med Ethics 2013;14:34.
37. US Food and Drug Administration. Risk evaluation and mitigation strategies 2015. www.fda.gov.
38. Marcano Belisario JS, Jamsek J, Huckvale K et al. Comparison of self-administered survey questionnaire responses collected using mobile apps versus other methods. Cochrane Database Syst Rev 2015;7:MR000042.
39. Kohane IS. Using electronic health records to drive discovery in disease genomics. Nat Rev Genet 2011;12:417-28.
40. Perlis RH, Iosifescu DV, Castro VM et al. Using electronic medical records to enable large-scale studies in psychiatry: treatment resistant depression as a model. Psychol Med 2012;42:41-50.
41. Gallagher PJ, Castro V, Fava M et al. Antidepressant response in patients with major depression exposed to NSAIDs: a pharmacovigilance study. Am J Psychiatry 2012;169:1065-72.
42. O'Dushlaine C, Ripke S, Ruderfer DM et al. Rare copy number variation in treatment-resistant major depressive disorder. Biol Psychiatry 2014;76:536-41.
43. Castro VM, Roberson AM, McCoy T et al. Stratifying risk for renal insufficiency among lithium-treated patients: an electronic health record study. Neuropsychopharmacology 2016;41:1138-43.
44. Blumenthal SR, Castro VM, Clements CC et al. An electronic health records study of long-term weight gain following antidepressant use. JAMA Psychiatry 2014;71:889-96.
45. Castro VM, Clements CC, Murphy SN et al. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ 2013;346:f288.
46. Perlis RH, Dennehy EB, Miklowitz DJ et al. Retrospective age at onset of bipolar disorder and outcome during two-year follow-up: results from the STEP-BD study. Bipolar Disord 2009;11:391-400.
47. Guo T, Xiang YT, Xiao L et al. Measurement-based care versus standard care for major depression: a randomized controlled trial with blind raters. Am J Psychiatry 2015;172:1004-13.
48. US Food and Drug Administration. Laboratory developed tests 2015. www.fda.gov.
49. Hall-Flavin DK, Winner JG, Allen JD et al. Using a pharmacogenomic algorithm to guide the treatment of depression. Transl Psychiatry 2012;2:e172.
50. Perlis RH, Patrick A, Smoller JW et al. When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study. Neuropsychopharmacology 2009;34:2227-36.
51. Winner J, Allen JD, Altar CA et al. Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression. Transl Psychiatry 2013;3:e242.
52. Fagerness J, Fonseca E, Hess GP et al. Pharmacogenetic-guided psychiatric intervention associated with increased adherence and cost savings. Am J Manag Care 2014;20:e146-56.